Caspar Schmelzer

Since joining Skadden, Mr. Schmelzer’s experience includes advising:

• CureVac N.V. in its all-stock acquisition by BioNTech SE that values CureVac N.V. at US$1.25 billion
• Axian Telecom in its acquisition of 19.7 million ordinary shares from Jumia Technologies AG, representing 8% of Jumia’s outstanding share capital
• MorphoSys AG in its:
  • €2.7 billion sale to, and public takeover by, Novartis and the simultaneous disposition of the worldwide marketing rights of its antibody drug Monjuvi to Incyte Corporation
  • cash capital increase with gross proceeds of approximately €102.7 million
  • US$1.7 billion acquisition of Constellation Pharmaceuticals, Inc. and its related US$2 billion financing from Royalty Pharma plc
  • U.S. IPO and dual listing of American depositary shares on Nasdaq
  • issuance of a US$300 million development funding bond
• Armira in its €30 million anchor investment as part of a €60 million private placement of new shares in tonies SE
• Medigene in its global cancer immunotherapy collaboration with BioNTech
• Silver Lake in its strategic partnership and investment in German publicly listed company Software AG via the purchase of €344 million aggregate principal amount of subordinated unsecured convertible notes. This is the first PIPE by any U.S. technology investment firm in a German public company
• Berenberg as sole global coordinator and joint bookrunner and Stifel as additional joint bookrunner in connection with a capital increase of Pacifico Renewables Yield AG
• SIGNA Sports United GmbH in connection with its US$3.3 billion initial public offering on the New York Stock Exchange as a result of the de-SPAC merger with Yucaipa Acquisition Corporation. The merger also included the acquisition of WiggleCRC Group
• the joint bookrunners, including Deutsche Bank and J.P. Morgan, in the €842 million private placement of ordinary bearer shares and listing on the Frankfurt Stock Exchange of ABOUT YOU Holding AG

Prior to joining Skadden, Mr. Schmelzer worked in the Frankfurt office of another law firm. His experience prior to joining Skadden includes advising:

• Siemens in the spin-off and listing of Siemens Energy
• BAWAG Group in its initial public offering
• the underwriters in the listing and offering of JOST Werke by way of a private placement
• Schaeffler AG as issuer’s counsel in the listing and offering by way of a private placement
• Sixt Leasing AG in its initial public offering
• the underwriters in the initial public offering of KION Group AG
• VTG in its €280 million rights offering
• Adidas in its €500 million equity-neutral convertible bond
• the underwriters in the €8 billion rights offering of Deutsche Bank
• thyssenkrupp in its €1.4 billion capital increase
• Diebold in its public takeover of Wincor Nixdorf AG
• Vonovia SE in the placement of secondary and primary shares with a total volume of €500 million
• Deutsche Wohnen in its public takeover of GSW Immobilien AG
• Deutsche Annington Immobilien SE (now: Vonovia) in its initial public offering